convalescent plasma treatment - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death or transfer to ICU 1.07 [0.73, 1.57]< 10%1 study (1/-)36.6 %highnot evaluable lowcrucial-
deaths 0.99 [0.64, 1.53]< 10%2 studies (2/-)51.7 %highnot evaluable lowcrucial-
clinical deterioration 0.72 [0.37, 1.43]< 158%2 studies (2/-)82.3 %highnot evaluable lowimportant-
mechanical ventilation 0.99 [0.54, 1.81]< 10%1 study (1/-)51.3 %highnot evaluable lowimportant-
viral clearance by day 7 1.20 [1.00, 1.44]> 10%1 study (1/-)97.4 %highnot evaluable lowimportant-
ICU admission 0.33 [0.07, 1.58]< 10%1 study (1/-)91.7 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.